Literature DB >> 18415699

Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients.

S Weller1, H Rosewich, J Gärtner.   

Abstract

Patients with defects in the biogenesis of peroxisomes include those with Zellweger syndrome spectrum (ZSS), a developmental and progressive metabolic disease with a distinct dysmorphic phenotype and varying severity. The diagnosis of ZSS relies on the clinical presentation and the biochemical evaluation of peroxisomal metabolites. Mutation detection in one out of twelve genes coding for proteins involved in the biogenesis of peroxisomes confirms the diagnosis. In the absence of pronounced clinical features of ZSS, neuroradiological findings may lead the way to the diagnosis. Cerebral magnetic resonance imaging (cMRI) pathology in ZSS consists of abnormal gyration pattern including polymicrogyria and pachygyria, leukencephalopathy, germinolytic cysts and heterotopias as reported by previous systematic studies including cMRI of a total of 34 ZSS patients, only five of whom had a severe phenotype. The present study evaluated the cMRI results of additional 18 patients, 6 with a severe and 12 with a milder ZSS phenotype. It confirms and extends knowledge of the characteristic cMRI pattern in ZSS patients. Besides an abnormal gyration pattern and delayed myelination or leukencephalopathy, brain atrophy was a common finding. Polymicrogyria and pachygyria were more common in patients with severe ZSS, while leukencephalopathy increases with age in patients with longer survival. Nevertheless, an abnormal gyration pattern might be more frequent in patients with a mild ZSS than deduced from previous studies. In addition, we discuss the differential diagnosis of the ZSS cMRI pattern and review investigations on the pathogenesis of the ZSS cerebral phenotype in mouse models of the disease.

Entities:  

Mesh:

Year:  2008        PMID: 18415699     DOI: 10.1007/s10545-008-0856-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  48 in total

1.  Generation of Pex5-loxP mice allowing the conditional elimination of peroxisomes.

Authors:  M Baes; M Dewerchin; A Janssen; D Collen; P Carmeliet
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

2.  MR imaging and MR spectroscopy in rhizomelic chondrodysplasia punctata.

Authors:  Angèle Viola; Sylviane Confort-Gouny; Jean-Philippe Ranjeva; Brigitte Chabrol; Charles Raybaud; Francisca Vintila; Patrick J Cozzone
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 3.  The peroxisome deficient PEX2 Zellweger mouse: pathologic and biochemical correlates of lipid dysfunction.

Authors:  P L Faust; H M Su; A Moser; H W Moser
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

4.  MRI findings of Zellweger syndrome.

Authors:  A Nakai; Y Shigematsu; K Nishida; Y Kikawa; Y Konishi
Journal:  Pediatr Neurol       Date:  1995-11       Impact factor: 3.372

5.  Clinical and biochemical spectrum of D-bifunctional protein deficiency.

Authors:  Sacha Ferdinandusse; Simone Denis; Petra A W Mooyer; Conny Dekker; Marinus Duran; Roelineke J Soorani-Lunsing; Eugen Boltshauser; Alfons Macaya; Jutta Gärtner; Charles B L M Majoie; Peter G Barth; Ronald J A Wanders; Bwee Tien Poll-The
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

Review 6.  Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain.

Authors:  P L Faust; D Banka; R Siriratsivawong; V G Ng; T M Wikander
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

7.  A mouse model for Zellweger syndrome.

Authors:  M Baes; P Gressens; E Baumgart; P Carmeliet; M Casteels; M Fransen; P Evrard; D Fahimi; P E Declercq; D Collen; P P van Veldhoven; G P Mannaerts
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

8.  The neuronal migration defect in mice with Zellweger syndrome (Pex5 knockout) is not caused by the inactivity of peroxisomal beta-oxidation.

Authors:  M Baes; P Gressens; S Huyghe; Nys K De; C Qi; Y Jia; G P Mannaerts; P Evrard; Veldhoven P P Van; P E Declercq; J K Reddy
Journal:  J Neuropathol Exp Neurol       Date:  2002-04       Impact factor: 3.685

9.  Neuroimaging features in a neonate with rhizomelic chondrodysplasia punctata.

Authors:  Suzanne Goh
Journal:  Pediatr Neurol       Date:  2007-11       Impact factor: 3.372

10.  Pex13 inactivation in the mouse disrupts peroxisome biogenesis and leads to a Zellweger syndrome phenotype.

Authors:  Megan Maxwell; Jonas Bjorkman; Tam Nguyen; Peter Sharp; John Finnie; Carol Paterson; Ian Tonks; Barbara C Paton; Graham F Kay; Denis I Crane
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

View more
  12 in total

1.  Zellweger Spectrum Disorder with Mild Phenotype Caused by PEX2 Gene Mutations.

Authors:  Andrea Mignarri; Claudia Vinciguerra; Antonio Giorgio; Sacha Ferdinandusse; Hans Waterham; Ronald Wanders; Enrico Bertini; Maria Teresa Dotti; Antonio Federico
Journal:  JIMD Rep       Date:  2012-01-29

Review 2.  Peroxisomes of the Brain: Distribution, Functions, and Associated Diseases.

Authors:  Rachayeeta Deb; Neha Joshi; Shirisha Nagotu
Journal:  Neurotox Res       Date:  2021-01-05       Impact factor: 3.911

3.  Diagnostic and prognostic value of in vivo proton MR spectroscopy for Zellweger syndrome spectrum patients.

Authors:  H Rosewich; P Dechent; C Krause; A Ohlenbusch; K Brockmann; J Gärtner
Journal:  J Inherit Metab Dis       Date:  2016-08-03       Impact factor: 4.982

Review 4.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

5.  Pristanic acid provokes lipid, protein, and DNA oxidative damage and reduces the antioxidant defenses in cerebellum of young rats.

Authors:  Estela Natacha Brandt Busanello; Vannessa Gonçalves Araujo Lobato; Ângela Zanatta; Clarissa Günther Borges; Anelise Miotti Tonin; Carolina Maso Viegas; Vanusa Manfredini; César Augusto João Ribeiro; Carmen Regla Vargas; Diogo Onofre Gomes de Souza; Moacir Wajner
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

Review 6.  Neonatal neuroimaging findings in inborn errors of metabolism.

Authors:  Andrea Poretti; Susan I Blaser; Maarten H Lequin; Ali Fatemi; Avner Meoded; Frances J Northington; Eugen Boltshauser; Thierry A G M Huisman
Journal:  J Magn Reson Imaging       Date:  2012-05-07       Impact factor: 4.813

Review 7.  Neurometabolic diseases of childhood.

Authors:  Zoltan Patay; Susan I Blaser; Andrea Poretti; Thierry A G M Huisman
Journal:  Pediatr Radiol       Date:  2015-09-07

8.  Induced pluripotent stem cell models of Zellweger spectrum disorder show impaired peroxisome assembly and cell type-specific lipid abnormalities.

Authors:  Xiao-Ming Wang; Wing Yan Yik; Peilin Zhang; Wange Lu; Ning Huang; Bo Ram Kim; Darryl Shibata; Madison Zitting; Robert H Chow; Ann B Moser; Steven J Steinberg; Joseph G Hacia
Journal:  Stem Cell Res Ther       Date:  2015-08-29       Impact factor: 6.832

Review 9.  Peroxisomes in brain development and function.

Authors:  Johannes Berger; Fabian Dorninger; Sonja Forss-Petter; Markus Kunze
Journal:  Biochim Biophys Acta       Date:  2015-12-11

10.  Neurometabolic Diagnosis in Children who referred as Neurodevelopmental Delay (A Practical Criteria, in Iranian Pediatric Patients).

Authors:  Parvaneh Karimzadeh; Narjes Jafari; Habibeh Nejad Biglari; Sayena Jabbehdari; Simin Khayat Zadeh; Farzad Ahmad Abadi; Azra Lotfi
Journal:  Iran J Child Neurol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.